查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1192974

全球卵巢癌治疗市场——按疗法（化疗、靶向疗法、其他）、分销渠道（医院药房、药店/零售药房、在线供应商）：全球机会分析和行业预测，2021-2031 年

Global Ovarian Cancer Drugs Market By Therapy (Chemotherapy, Targeted Therapy, Others), By Distribution Channel (Hospital Pharmacy, Drug Stores and Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 189 Pages | 商品交期: 2-3个工作天内

价格

2021 年，全球卵巢癌治疗药物市场将达到 22.838 亿美元，2022 年至 2031 年的复合年增长率为 8.4%，预计 2031 年将达到 50.6359 亿美元。

卵巢癌是在卵巢中形成的细胞增殖。 这些细胞繁殖迅速，可以侵入和破坏健康的身体组织。 女性生殖道有两个卵巢，一个在子宫的每一侧。 每个卵巢大约有杏仁那么大，会产生卵子 (ova) 以及孕激素和雌激素。 卵巢癌的治疗通常包括手术和化疗。 卵巢癌的症状包括腹胀和肿胀、进食后饱腹感、体重减轻、骨盆不适、疲劳、腰痛、排便习惯改变和尿频增加。

由于女性人口老龄化、卵巢癌的增加、创新药物的推出、医疗保健支出的增加、政府支持的加强等，预计在预测期内，卵巢癌治疗市场将显着增长。 此外，增加研发投资、强大的管道候选人的存在以及新兴市场公众对疾病预防意识的增强正在进一步推动市场的增长。 然而，药物开发的高成本和失败的可能性预计会阻碍市场增长。 另一方面，癌症研究的进步和个性化医疗的努力有望为卵巢癌药物市场提供新的增长机会。

卵巢癌治疗市场根据疗法、分销渠道和地区进行细分。 通过治疗，市场被细分为化疗、靶向治疗等。 按分销渠道，市场分为医院药房、药店和零售药房以及在线供应商。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析

第 4 章全球卵巢癌治疗市场：按治疗分类

  • 概览
    • 市场规模和预测
  • 化疗
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 靶向药物
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
    • 卵巢癌靶向治疗药物的全球市场：按治疗类别分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 5 章全球卵巢癌药物市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长因素和机遇
    • 各地区的市场规模和预测
    • 市场份额分析：按国家/地区分类
  • 药店、零售药店
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 在线提供商
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 6 章。全球卵巢癌药物市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测：按处理方法
    • 北美市场规模和预测：按分销渠道
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按处理方法
    • 欧洲市场规模和预测：按分销渠道
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲
  • 亚太地区
    • 主要趋势和机会
    • 亚太地区市场规模和按处理方法预测
    • 亚太市场规模和预测：按分销渠道
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 日本
      • 中国
      • 澳大利亚
      • 印度
      • 韩国
      • 其他亚太地区
  • 拉美
    • 主要趋势和机会
    • LAMEA 市场规模和预测：按处理方法
    • LAMEA 市场规模和预测：按分销渠道
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第七章商业条件

  • 介绍
  • 最成功的策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第八章公司简介

  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Services, Inc.
  • GlaxoSmithKline Plc
  • Boehringer Ingelheim International GmbH
  • Clovis Oncology
  • Abbvie Inc
  • Pfizer, Inc.
  • Merck KGaA
  • AstraZeneca
  • Amgen Inc.
Product Code: A00273

The global ovarian cancer drugs market accounted for $2,283.8 million in 2021, and is expected to reach $5,063.59 million by 2031, registering a CAGR of 8.4% from 2022 to 2031.

Ovarian cancer is a growth of cells that forms in the ovaries. The cells multiply quickly and can invade and destroy healthy body tissue. The female reproductive system contains two ovaries, one on each side of the uterus. Each ovary, which is about the size of an almond, produces Egg (ova) along with the hormones progesterone and estrogen. Ovarian cancer treatment usually involves surgery and chemotherapy. Signs and symptoms of ovarian cancer may include abdominal bloating or swelling, quickly feeling full when eating, weight loss, discomfort in pelvic area, fatigue, back pain, changes in bowel habits and a frequent need to urinate.

It is estimated that ovarian cancer drugs market is expected to experience significant growth during the forecast period owing to increase in aging population of women, rise in prevalence of ovarian cancer, launch of innovative medications, boost in healthcare expenditure, and higher government support. In addition, increase in investment by players in R&D, presence of robust pipeline candidates, and increase in public awareness about the disease prevention in developing regions further facilitate the growth of the market. However, high cost of drug development and threat of failure are expected to impede the market growth. In contrast, advancement of cancer research and personalized medicine approach are factors that present new pathway in the industry are anticipated to provide significant growth opportunities for the ovarian cancer drugs market.

The ovarian cancer drugs market is segmented on the basis of therapy, distribution channel and region. Depending on therapy, the market is classified into chemotherapy, targeted therapy and others. By distribution channel, the market is classified into hospital pharmacy, drug stores and retail pharmacy, and online providers.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global ovarian cancer drugs market. The key companies profiled in the report include AbbVie, Pfizer, Inc., Merck Kagan, AstraZeneca, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc, Boehringer Ingelheim International GmbH, Clovis Oncology, and Amgen.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global ovarian cancer drugs market analysis from 2021 to 2031 to identify the prevailing global ovarian cancer drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global ovarian cancer drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global global ovarian cancer drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapy

  • Chemotherapy
  • Targeted Therapy
    • Drug Class
    • PARP Inhibitors
    • Angiogenesis Inhibitors
    • Others
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Drug Stores and Retail Pharmacy
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Abbvie Inc
    • Pfizer, Inc.
    • Merck KGaA
    • AstraZeneca
    • F. Hoffmann-La Roche AG
    • Clovis Oncology
    • Amgen Inc.
    • Johnson & Johnson Services, Inc.
    • Boehringer Ingelheim International GmbH
    • GlaxoSmithKline plc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Chemotherapy
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Targeted Therapy
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
    • 4.3.4 Targeted Therapy Global Ovarian Cancer Drugs Market by Drug Class
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country

CHAPTER 5: GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Hospital Pharmacy
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Drug Stores and Retail Pharmacy
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4 Online Providers
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country

CHAPTER 6: GLOBAL OVARIAN CANCER DRUGS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Therapy
    • 6.2.3 North America Market size and forecast, by Distribution Channel
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Key market trends, growth factors and opportunities
      • 6.2.4.1.2 Market size and forecast, by Therapy
      • 6.2.4.1.3 Market size and forecast, by Distribution Channel
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Key market trends, growth factors and opportunities
      • 6.2.4.2.2 Market size and forecast, by Therapy
      • 6.2.4.2.3 Market size and forecast, by Distribution Channel
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Key market trends, growth factors and opportunities
      • 6.2.4.3.2 Market size and forecast, by Therapy
      • 6.2.4.3.3 Market size and forecast, by Distribution Channel
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Therapy
    • 6.3.3 Europe Market size and forecast, by Distribution Channel
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Key market trends, growth factors and opportunities
      • 6.3.4.1.2 Market size and forecast, by Therapy
      • 6.3.4.1.3 Market size and forecast, by Distribution Channel
      • 6.3.4.2 France
      • 6.3.4.2.1 Key market trends, growth factors and opportunities
      • 6.3.4.2.2 Market size and forecast, by Therapy
      • 6.3.4.2.3 Market size and forecast, by Distribution Channel
      • 6.3.4.3 UK
      • 6.3.4.3.1 Key market trends, growth factors and opportunities
      • 6.3.4.3.2 Market size and forecast, by Therapy
      • 6.3.4.3.3 Market size and forecast, by Distribution Channel
      • 6.3.4.4 Italy
      • 6.3.4.4.1 Key market trends, growth factors and opportunities
      • 6.3.4.4.2 Market size and forecast, by Therapy
      • 6.3.4.4.3 Market size and forecast, by Distribution Channel
      • 6.3.4.5 Spain
      • 6.3.4.5.1 Key market trends, growth factors and opportunities
      • 6.3.4.5.2 Market size and forecast, by Therapy
      • 6.3.4.5.3 Market size and forecast, by Distribution Channel
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Key market trends, growth factors and opportunities
      • 6.3.4.6.2 Market size and forecast, by Therapy
      • 6.3.4.6.3 Market size and forecast, by Distribution Channel
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Therapy
    • 6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 Japan
      • 6.4.4.1.1 Key market trends, growth factors and opportunities
      • 6.4.4.1.2 Market size and forecast, by Therapy
      • 6.4.4.1.3 Market size and forecast, by Distribution Channel
      • 6.4.4.2 China
      • 6.4.4.2.1 Key market trends, growth factors and opportunities
      • 6.4.4.2.2 Market size and forecast, by Therapy
      • 6.4.4.2.3 Market size and forecast, by Distribution Channel
      • 6.4.4.3 Australia
      • 6.4.4.3.1 Key market trends, growth factors and opportunities
      • 6.4.4.3.2 Market size and forecast, by Therapy
      • 6.4.4.3.3 Market size and forecast, by Distribution Channel
      • 6.4.4.4 India
      • 6.4.4.4.1 Key market trends, growth factors and opportunities
      • 6.4.4.4.2 Market size and forecast, by Therapy
      • 6.4.4.4.3 Market size and forecast, by Distribution Channel
      • 6.4.4.5 South Korea
      • 6.4.4.5.1 Key market trends, growth factors and opportunities
      • 6.4.4.5.2 Market size and forecast, by Therapy
      • 6.4.4.5.3 Market size and forecast, by Distribution Channel
      • 6.4.4.6 Rest of Asia-Pacific
      • 6.4.4.6.1 Key market trends, growth factors and opportunities
      • 6.4.4.6.2 Market size and forecast, by Therapy
      • 6.4.4.6.3 Market size and forecast, by Distribution Channel
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Therapy
    • 6.5.3 LAMEA Market size and forecast, by Distribution Channel
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Key market trends, growth factors and opportunities
      • 6.5.4.1.2 Market size and forecast, by Therapy
      • 6.5.4.1.3 Market size and forecast, by Distribution Channel
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Key market trends, growth factors and opportunities
      • 6.5.4.2.2 Market size and forecast, by Therapy
      • 6.5.4.2.3 Market size and forecast, by Distribution Channel
      • 6.5.4.3 South Africa
      • 6.5.4.3.1 Key market trends, growth factors and opportunities
      • 6.5.4.3.2 Market size and forecast, by Therapy
      • 6.5.4.3.3 Market size and forecast, by Distribution Channel
      • 6.5.4.4 Rest of LAMEA
      • 6.5.4.4.1 Key market trends, growth factors and opportunities
      • 6.5.4.4.2 Market size and forecast, by Therapy
      • 6.5.4.4.3 Market size and forecast, by Distribution Channel

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 F. Hoffmann-La Roche AG
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Johnson & Johnson Services, Inc.
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 GlaxoSmithKline Plc
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 Boehringer Ingelheim International GmbH
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Clovis Oncology
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 Abbvie Inc
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Pfizer, Inc.
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Merck KGaA
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 AstraZeneca
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 Amgen Inc.
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. GLOBAL OVARIAN CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. GLOBAL OVARIAN CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. GLOBAL OVARIAN CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. GLOBAL OVARIAN CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. GLOBAL TARGETED THERAPY GLOBAL OVARIAN CANCER DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. GLOBAL OVARIAN CANCER DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. GLOBAL OVARIAN CANCER DRUGS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. GLOBAL GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. GLOBAL OVARIAN CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. GLOBAL OVARIAN CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. GLOBAL OVARIAN CANCER DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. GLOBAL OVARIAN CANCER DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. GLOBAL OVARIAN CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. GLOBAL OVARIAN CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. GLOBAL OVARIAN CANCER DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. NORTH AMERICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. NORTH AMERICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. U.S. GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. GERMANY GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. GERMANY GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. FRANCE GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. FRANCE GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. UK GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. UK GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. ITALY GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. ITALY GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. SPAIN GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. SPAIN GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. REST OF EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. REST OF EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. JAPAN GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. JAPAN GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. CHINA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. CHINA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. AUSTRALIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. AUSTRALIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. INDIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. INDIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. SOUTH KOREA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. SOUTH KOREA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. REST OF ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. REST OF ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. BRAZIL GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. BRAZIL GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. SAUDI ARABIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. SAUDI ARABIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. SOUTH AFRICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. SOUTH AFRICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. REST OF LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. REST OF LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67.F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 68.F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 69.F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 70.F. HOFFMANN-LA ROCHE AG: NET SALES
  • TABLE 71.F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
  • TABLE 72.JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
  • TABLE 73.JOHNSON & JOHNSON SERVICES, INC.: OPERATING SEGMENTS
  • TABLE 74.JOHNSON & JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
  • TABLE 75.JOHNSON & JOHNSON SERVICES, INC.: NET SALES
  • TABLE 76.JOHNSON & JOHNSON SERVICES, INC.: KEY STRATERGIES
  • TABLE 77.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 78.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 79.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 80.GLAXOSMITHKLINE PLC: NET SALES
  • TABLE 81.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 82.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 83.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OPERATING SEGMENTS
  • TABLE 84.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 85.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES
  • TABLE 86.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATERGIES
  • TABLE 87.CLOVIS ONCOLOGY: COMPANY SNAPSHOT
  • TABLE 88.CLOVIS ONCOLOGY: OPERATING SEGMENTS
  • TABLE 89.CLOVIS ONCOLOGY: PRODUCT PORTFOLIO
  • TABLE 90.CLOVIS ONCOLOGY: NET SALES
  • TABLE 91.CLOVIS ONCOLOGY: KEY STRATERGIES
  • TABLE 92.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 93.ABBVIE INC: OPERATING SEGMENTS
  • TABLE 94.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 95.ABBVIE INC: NET SALES
  • TABLE 96.ABBVIE INC: KEY STRATERGIES
  • TABLE 97.PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 98.PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 99.PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 100.PFIZER, INC.: NET SALES
  • TABLE 101.PFIZER, INC.: KEY STRATERGIES
  • TABLE 102.MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 103.MERCK KGAA: OPERATING SEGMENTS
  • TABLE 104.MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 105.MERCK KGAA: NET SALES
  • TABLE 106.MERCK KGAA: KEY STRATERGIES
  • TABLE 107.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 108.ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 109.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 110.ASTRAZENECA: NET SALES
  • TABLE 111.ASTRAZENECA: KEY STRATERGIES
  • TABLE 112.AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 113.AMGEN INC.: OPERATING SEGMENTS
  • TABLE 114.AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 115.AMGEN INC.: NET SALES
  • TABLE 116.AMGEN INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.GLOBAL OVARIAN CANCER DRUGS MARKET SEGMENTATION
  • FIGURE 2.GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031
  • FIGURE 3.GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.GLOBAL OVARIAN CANCER DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.GLOBAL OVARIAN CANCER DRUGS MARKET,BY THERAPY,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
  • FIGURE 16.GLOBAL OVARIAN CANCER DRUGS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
  • FIGURE 20.GLOBAL OVARIAN CANCER DRUGS MARKET BY REGION,2021
  • FIGURE 21.U.S. GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 22.CANADA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 23.MEXICO GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 24.GERMANY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 25.FRANCE GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 26.UK GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 27.ITALY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 28.SPAIN GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 29.REST OF EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 30.JAPAN GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 31.CHINA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 32.AUSTRALIA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 33.INDIA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 34.SOUTH KOREA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 36.BRAZIL GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 37.SAUDI ARABIA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH AFRICA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 39.REST OF LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 43.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 44.COMPETITIVE DASHBOARD
  • FIGURE 45.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 46.F. HOFFMANN-LA ROCHE AG.: NET SALES ($MILLION)
  • FIGURE 47.JOHNSON & JOHNSON SERVICES, INC..: NET SALES ($MILLION)
  • FIGURE 48.GLAXOSMITHKLINE PLC.: NET SALES ($MILLION)
  • FIGURE 49.BOEHRINGER INGELHEIM INTERNATIONAL GMBH.: NET SALES ($MILLION)
  • FIGURE 50.CLOVIS ONCOLOGY.: NET SALES ($MILLION)
  • FIGURE 51.ABBVIE INC.: NET SALES ($MILLION)
  • FIGURE 52.PFIZER, INC..: NET SALES ($MILLION)
  • FIGURE 53.MERCK KGAA.: NET SALES ($MILLION)
  • FIGURE 54.ASTRAZENECA.: NET SALES ($MILLION)
  • FIGURE 55.AMGEN INC..: NET SALES ($MILLION)